The Experts below are selected from a list of 16959 Experts worldwide ranked by ideXlab platform
Maurie Markman - One of the best experts on this subject based on the ideXlab platform.
-
Elevated Serum CA-125 in a Patient with Follicular Lymphoma and a History of Ovarian CAncer.
Case reports in oncology, 2011Co-Authors: Rachna Anand, Maurie MarkmanAbstract:A patient with a previous history of epithelial ovarian CAncer presented to her physician with diffuse adenopathy. On subsequent evaluation, she was found to have a follicular lymphoma. Work-up revealed an elevated serum CA-125 Antigen level, raising the question of whether the laboratory abnormality represented evidence of recurrence of the original epithelial CAncer. The subsequent major decline in this tumor marker following treatment directed to the lymphoma provided strong support for the conclusion that the elevated CA-125 was secondary to this malignant process and not ovarian CAncer.
-
Major CliniCAl Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian CAncer.
Case reports in oncology, 2009Co-Authors: Jian Chen, Maurie MarkmanAbstract:A patient with extensive and painful chest wall involvement from a metastatic borderline CAncer of the ovary was treated with a CArboplatin plus paclitaxel chemotherapy regimen. She achieved a rather dramatic improvement of pain control, a signifiCAnt biochemiCAl response with 75% reduction of the CA-125 Antigen level, but only limited radiographic tumor regression. This experience emphasizes the potential cliniCAl utility of platinum-based cytotoxic chemotherapy in the setting of symptomatic advanced borderline ovarian CAncer.
-
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian CAncers: a Gynecologic Oncology Group study.
Cancer, 2009Co-Authors: Chunqiao Tian, Maurie Markman, Richard J. Zaino, Robert F. Ozols, William Mcguire, Franco M. Muggia, Peter G. Rose, David R. Spriggs, Deborah K. ArmstrongAbstract:Background There are limited data regarding unique cliniCAl or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian CAncers (EOC), particularly the relationship between CA-125 Antigen levels and prognosis.
-
signifiCAnce of early changes in the serum CA 125 Antigen level on overall survival in advanced ovarian CAncer
Gynecologic Oncology, 2006Co-Authors: Maurie Markman, Massimo Federico, Edward V Hannigan, David S AlbertsAbstract:Abstract Objective. The relationship between survival and early changes in the serum level of the CA-125 Antigen in patients with advanced ovarian CAncer remains poorly defined. Methods. To explore this issue, the serum CA-125 values from 101 patients with advanced ovarian CAncer who participated in a Southwest Oncology Group trial (SWOG 8412), which compared the systemic delivery of cisplatin/cyclophosphamide vs. CArboplatin/cyclophosphamide (both delivered every 28 days for 6 cycles) in suboptimal residual stage III and IV ovarian CAncer, were evaluated. All patients in this analysis had CA-125 values available for at least 8 weeks following initiation of chemotherapy. Cox proportional hazards regression was used in multivariate analysis to determine the prognostic signifiCAnce of the CA-125 concentration. Results. While pretreatment CA-125 values did not correlate with survival, the concentration of this tumor marker 8 weeks after initiation of therapy was a powerful independent prognostic factor. The median survivals for patients ( n = 51) with a CA-125 n = 50) with a CA-125 > 35 U/ml, at this time point, were 26 months and 15 months, respectively ( P = 0.0001). Further, women with serum CA-125 values 50% of their baseline value ( P = 0.0003). Conclusion. Reduction in the serum CA-125 concentration over the initial two cycles of platinum-based chemotherapy is a powerful independent predictor of survival for patients with suboptimal stage III or IV ovarian CAncer. Patients without signifiCAnt declines in CA-125 after two cycles of platinum-based chemotherapy have a particularly poor prognosis.
-
Examples of the marked variability in the relationship between the serum CA-125 Antigen level and CAncer-related symptoms in ovarian CAncer.
Gynecologic oncology, 2004Co-Authors: Maurie Markman, Kenneth Webster, Kristine M. Zanotti, Gertrude Peterson, Barbara Kulp, Jerome L. BelinsonAbstract:Abstract Objective . While the cliniCAl utility of the serum CA-125 Antigen level in demonstrating objective evidence of regression or progression of disease in women with ovarian CAncer is well-established, the relationship between both the absolute value of this tumor maker, or its rate of change over time, and the short-term cliniCAl course (e.g., development of CAncer-related symptoms) in individual patients remains poorly defined. CAse reports . Five women currently under the CAre of physicians in the Gynecologic CAncer program of the Cleveland Clinic demonstrate the marked variability in the correlation between the serum CA-125 Antigen and the natural history of disease for individual patients with ovarian or primary peritoneal CAncers. In these CAses, persistent elevations (>100 units/ml for >2 years), rapid changes ( 2000 units/ml over ≤2 months), or extremely high CA-125 values (>5000 units/ml) failed to accurately predict the presence, time to development, or severity of symptoms. Conclusion . In the second-line and palliative management of ovarian or primary peritoneal CAncers, it is important to emphasize the critiCAl need for cliniCAl judgement in the decision to initiate or alter therapy in individual patients based solely on changes in the serum level of the CA-125 Antigen.
Jerome L. Belinson - One of the best experts on this subject based on the ideXlab platform.
-
Examples of the marked variability in the relationship between the serum CA-125 Antigen level and CAncer-related symptoms in ovarian CAncer.
Gynecologic oncology, 2004Co-Authors: Maurie Markman, Kenneth Webster, Kristine M. Zanotti, Gertrude Peterson, Barbara Kulp, Jerome L. BelinsonAbstract:Abstract Objective . While the cliniCAl utility of the serum CA-125 Antigen level in demonstrating objective evidence of regression or progression of disease in women with ovarian CAncer is well-established, the relationship between both the absolute value of this tumor maker, or its rate of change over time, and the short-term cliniCAl course (e.g., development of CAncer-related symptoms) in individual patients remains poorly defined. CAse reports . Five women currently under the CAre of physicians in the Gynecologic CAncer program of the Cleveland Clinic demonstrate the marked variability in the correlation between the serum CA-125 Antigen and the natural history of disease for individual patients with ovarian or primary peritoneal CAncers. In these CAses, persistent elevations (>100 units/ml for >2 years), rapid changes ( 2000 units/ml over ≤2 months), or extremely high CA-125 values (>5000 units/ml) failed to accurately predict the presence, time to development, or severity of symptoms. Conclusion . In the second-line and palliative management of ovarian or primary peritoneal CAncers, it is important to emphasize the critiCAl need for cliniCAl judgement in the decision to initiate or alter therapy in individual patients based solely on changes in the serum level of the CA-125 Antigen.
-
Serum CA-125 as a marker of disease activity in uterine papillary serous CArcinoma.
Journal of cancer research and clinical oncology, 1999Co-Authors: Drew Abramovich, Maurie Markman, Kenneth Webster, Alexander W. Kennedy, Jerome L. BelinsonAbstract:Papillary serous CArcinoma of the endometrium exhibits many cliniCAl features of ovarian CAncer, including a high metastatic potential and response to platinum-based chemotherapy. We investigated the cliniCAl utility of the serum CA-125 Antigen level, an established marker of response or progression in ovarian CAncer, to serve as a indiCAtor of these events in patients with this highly malignant subtype of endometrial CAncer. Of 21 individuals with this CAncer treated in our program from 11/91 to 6/97, 16 had baseline CA-125 determinations prior to the administration of chemotherapy, of whom 13 were elevated above the normal range. Of these 13 patients, 8 (57%) experienced either a major reduction or normalization of CA-125 levels following therapy, consistent with their cliniCAl course at that point in time. Similarly, of 11 patients who ultimately relapsed, 8 (73%) were found to have a rise in the CA-125 Antigen level which closely corresponded to, or proceeded, cliniCAl relapse. A single patient was demonstrated to have disease progression with a declining level of CA-125. We conclude the serum CA-125 Antigen level is a useful indiCAtor of disease response or progression in individuals with papillary serous CArcinoma of the endometrium.
Mathias Onsrud - One of the best experts on this subject based on the ideXlab platform.
-
tissue polypeptide specific Antigen and CA 125 as serum tumor markers in ovarian CArcinoma
Tumor Biology, 1994Co-Authors: Ayman Shabana, Mathias OnsrudAbstract:The serum levels of tissue polypeptide-specific (TPS) Antigen were measured using the M3 monoclonal antibody in an enzyme immunoassay in 33 patients with ovarian CAncer, in 26 women with benign pelvic masses and in 26 women with a laparoscopiCAlly proven normal pelvis. The results were compared with the serum levels of the CA 125 Antigen. At a cutoff level of 135 U/l for TPS and 20 U/l for CA 125 (95th percentile of the healthy controls), the sensitivity of the tests for detecting a malignant tumor was 77% for TPS and 87% for CA 125. The specificities were 85% for TPS and 92% for CA 125. Adding TPS to CA 125 did not increase the diagnostic values compared to using the CA 125 test alone. For both markers, the rate of positivity was higher in advanced stage than in early-stage ovarian CAncer. No correlation between marker levels and survival was found. Serial determinations performed with 4 patients during therapy and follow-up showed that both TPS and CA 125 are good predictors of tumor response and recurrence.
H Abramovici - One of the best experts on this subject based on the ideXlab platform.
-
follow up of small postmenopausal ovarian cysts using vaginal ultrasound and CA 125 Antigen
Journal of Clinical Ultrasound, 1996Co-Authors: Ron Auslender, I Atlas, A Lissak, Jacob Bornstein, J Atad, H AbramoviciAbstract:To determine the natural history of small, simple ovarian cysts in post-menopausal women, 51 postmenopausal patients with small (<5 cm), smooth, aseptate, hypoechogenic ovarian cysts, without ascites, were followed by vaginal ultrasound examinations every 3 months for an average period of 2.5 years. In 34, CA-125 Antigen was measured and found to be within normal limits. None of the cysts showed changes in texture, nor did ascites appear. The CA-125 Antigen serum levels remained low. The mean size of the cysts decreased with time. There was no statistiCAlly signifiCAnt correlation between the initial size of the cyst, its tendency to grow or shrink, and the absolute CA-125 serum level. Our findings support the option of a conservative follow-up by repeated ultrasonic and CA-125 Antigen examinations of small, simple cysts in postmenopausal women. © 1996 John Wiley & Sons, Inc.
-
Follow-up of small, postmenopausal ovarian cysts using vaginal ultrasound and CA-125 Antigen
Journal of clinical ultrasound : JCU, 1996Co-Authors: Ron Auslender, I Atlas, A Lissak, Jacob Bornstein, J Atad, H AbramoviciAbstract:To determine the natural history of small, simple ovarian cysts in post-menopausal women, 51 postmenopausal patients with small (
Hiroshi Kobayashi - One of the best experts on this subject based on the ideXlab platform.
-
Quantitative and qualitative assessment of CA-125 production by human endometrial epithelial cells: comparison of eutopic and heterotopic epithelial cells.
International journal of cancer, 1993Co-Authors: Hiroshi Kobayashi, Toshihiko Terao, W. Ida, Yoshiro KawashimaAbstract:We have established an in vitro system for the culture of epithelial cells (ECs) from human uterine endometrium to examine the production of CA 125 and to characterize the CA-125 Antigen purified from the conditioned media. CA-125 secretion was higher in heterotopic ECs than in eutopic ECs and it was more signifiCAnt after heterotopic ECs reached confluence than during the logarithmic growth phase. CA-125 expression was observed mainly in the G0/G,-phase. CA-125 expression on cell membranes did not correlate with the volume of CA 125 released per cell, and there was no amplifiCAtion of CA-125 expression in heterotopic EC membranes. Treatment of the purified CA-125 Antigen with 6 M urea yielded a much lower molecular-mass peak (200 kDa). The results of Western blot indiCAted the presence of a single polydisperse band of 200 kDa in the conditioned media from eutopic ECs, whereas 2 major CA-125 isoforms of 200 kDa and 110 kDa, as well as 2 minor forms of 100 kDa and 70 kDa, were observed in the conditioned media of the heterotopic ECs. We conclude that, in heterotopic ECs, the 1 10-kDa CA-125 is more prominent than the 200-kDa Antigen, and that the elevation of CA-125 levels in the conditioned media could be attributed to signifiCAntly increased release of I 10-kDa CA-125 from heterotopic ECs.
-
Characterization of CA 125 Antigen identified by monoclonal antibodies that recognize different epitopes
Clinical biochemistry, 1993Co-Authors: Hiroshi Kobayashi, Hidekazu Ohi, Nobuhiko Moniwa, Hiromitsu Shinohara, Toshihiko TeraoAbstract:Abstract The present study was undertaken to characterize the Antigenic determinant of the CA 125 macromolecules recognized by newly developed monoclonal antibodies (M 11, 130-22, 145-9, 602-1, and 602-6), examine their relationship among the epitopes recognized by these antibodies, and develop a series of ezyme-linked immunosorbent assays (ELISAs) in which various combinations of antibodies are used in a double-determinant sandwich mode. The Antigenic determinants of CA 125 were characterized by several methods including competitive ELISA and immunoblotting. These antibodies, as well as OC 125, reacted with ovarian CAncer (HOC-l) cell extract in a dose-dependent manner. Purified CA 125 Antigen with a molecular mass of less than 200 kDa (CA 125 / 200 kDa, whereas the reactivity of OC 125 was completely inhibited by CA 125 >/ 200 kDa. The Antigenic determinants of M 11, 145-9, 602-6, 130-22, and 602-1 were closely related to each other, in this order; whereas OC 125 recognized a different epitope on a structurally identiCAl molecule. The use of these monoclonal antibodies in combination with each other may result in the development of a more specific and sensitive assay for CA 125.
-
Molecular characteristics of the CA 125 Antigen produced by human endometrial epithelial cells: comparison between eutopic and heterotopic epithelial cells.
American journal of obstetrics and gynecology, 1993Co-Authors: Hiroshi Kobayashi, Toshihiko Terao, W. Ida, Yoshiro KawashimaAbstract:Objective: To characterize the CA 125 Antigen purified from the conditioned media using an in vitro system that we have established for the culture of epithelial cells from human uterine endometrium. Study design: CA 125 was purified separately from the conditioned media of eutopic and heterotopic epithelial cells by gel chromatography and OC 125 immunoaffinity column chromatography. Results: Western blot analysis of conditioned media from eutopic epithelial cells revealed a single polydisperse band of 200 kd, whereas two major CA 125 isoforms of 200 and 110 kd, as well as two minor forms of 100 and 70 kd, were observed in heterotopic epithelial cells. The 110 kd CA 125 was more prominent than the 200 kd Antigen in heterotopic epithelial cells. Conclusion: These results strongly suggest that CA 125 Antigens purified by immunoaffinity chromatography have different molecular mass in eutopic and heterotopic epithelial cells even though the OC 125 binding site may remain intact.
-
CliniCAl evaluation of circulating serum sialyl Tn Antigen levels in patients with epithelial ovarian CAncer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991Co-Authors: Hiroshi Kobayashi, Toshihiko Terao, Yoshiro KawashimaAbstract:Sialyl Tn Antigen (NeuAc alpha 2----6GalNac alpha 1----0-Ser/Thr [STN]) with Antigenic specificity in the core structure of mucin-type CArbohydrate chains has been determined. In the present study, we evaluated the cliniCAl signifiCAnce of this new CArbohydrate Antigen, STN, in patients with epithelial ovarian CAncer. With the use of a radioimmunoassay developed to detect STN Antigen in serum, elevated (greater than or equal to 32.6 U/mL) Antigen levels were observed in 50.0% of patients with ovarian CAncer. In contrast, 3.8% of healthy individuals had STN Antigen levels greater than or equal to 32.6 U/mL. In 9.6% of patients with benign gynecologic diseases and 0% of pregnant women, there were elevated levels of STN Antigen. There was a signifiCAnt difference (P less than .001) in STN Antigen levels between patients with ovarian CAncer and patients with benign gynecologic diseases, pregnant women, or the controls. The mean +/- SD for all evaluated samples of ovarian CAncer was 109.2 +/- 146.8 U/mL. Both the mean values and the positive rate increased as the stage advanced. Classified according to the histologic type, the highest positive rate (61.0%) was observed in mucinous adenoCArcinoma. The usefulness of STN Antigen as a circulating tumor marker in ovarian CAncer was estimated as follows: sensitivity 50.0%, specificity 93.5%, positive predictive value 72.2%, negative predictive value 84.7%, and diagnostic value 46.8%. Serum STN Antigen levels were elevated in 12 of 33 patients with ovarian CAncer who had serum CA 125 Antigen levels less than 35 U/mL. While CA 125 Antigen levels were elevated in 74.6% and STN Antigen levels were elevated in 50.0% of the same population, the use of both assays indiCAted the sensitivity of detection of 83.8% in the population studied.
